Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · VivoSim Labs, INC. (VIVS)

VivoSim Labs receives Nasdaq bid price deficiency notice; has until February 16, 2027

Negative Impact 4 of 5 legal/regulatory Written later

VivoSim Labs (VIVS) received a Nasdaq notice on August 17, 2026 saying its stock no longer met the $1 minimum bid price over 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance, and its shares continue to trade on the Nasdaq Capital Market for now. The company has proposed a reverse stock split, which requires stockholder approval, and a failure to regain compliance could lead to delisting proceedings.

Key points

  • Nasdaq notice received August 17, 2026 under Listing Rule 5550(a)(2) for the $1 minimum bid price
  • Compliance deadline is February 16, 2027; regaining it requires a closing bid of at least $1 for ten consecutive business days
  • Proposed reverse stock split ratio range of 1-for-5 to 1-for-20, subject to stockholder approval in the 2026 annual meeting proxy
  • Notice has no immediate effect on listing or trading; ticker remains VIVS

The filing

CompanyVivoSim Labs, INC. (VIVS)
Form8-K, current report
Filed with the SECAug 21, 2026, 4:05 PM ET
Accession number0001193125-26-361085

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.